title: A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.
abstract: Smokers experience aberrant gene promoter methylation in their bronchial cells, which may predispose to the development of neoplasia. Hydralazine is a DNA demethylating agent, and valproic acid is a histone deacetylase inhibitor, and both have modest but synergistic anticancer activity in vitro. We conducted a phase I trial combining valproic acid and hydralazine to determine the maximally tolerated dose (MTD) of hydralazine in combination with a therapeutic dose of valproic acid in patients with advanced, unresectable, and previously treated solid cancers. Twenty females and nine males were enrolled, with a median age of 57 years and a median ECOG performance status of 0. Grade 1 lymphopenia and fatigue were the most common adverse effects. Three subjects withdrew for treatment-related toxicities occurring after the DLT observation period, including testicular edema, rash, and an increase in serum lipase accompanied by hyponatremia in one subject each. A true MTD of hydralazine in combination with therapeutic doses of valproic acid was not reached in this trial, and the planned upper limit of hydralazine investigated in this combination was 400 mg/day without grade 3 or 4 toxicities. A median number of two treatment cycles were delivered. One partial response by Response Evaluation Criteria In Solid Tumors criteria was observed, and five subjects experienced stable disease for 3 to 6 months. The combination of hydralazine and valproic acid is simple, nontoxic, and might be appropriate for chemoprevention or combination with other cancer treatments. This trial supports further investigation of epigenetic modification as a new therapeutic strategy.
authors.affiliation: University of Pittsburg Cancer Institute, Pittsburgh, PA.
authors.forename: Julie
authors.initials: J
authors.lastname: Bauman
authors.affiliation: University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Monte
authors.initials: M
authors.lastname: Shaheen
authors.affiliation: University of Vermont Cancer Center, Burlington, VT.
authors.forename: Claire F
authors.initials: CF
authors.lastname: Verschraegen
authors.affiliation: Lovelace Respiratory Research Institute Albuquerque, NM.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Belinsky
authors.affiliation: University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: M
authors.initials: M
authors.lastname: Houman Fekrazad
authors.affiliation: University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Fa-Chyi
authors.initials: FC
authors.lastname: Lee
authors.affiliation: University of New Mexico Cancer Center, Albuquerque, NM.
authors.forename: Ian
authors.initials: I
authors.lastname: Rabinowitz
authors.affiliation: Sharp Rees-Stealy Medical Group, San Diego, CA.
authors.forename: Meera
authors.initials: M
authors.lastname: Ravindranathan
authors.affiliation: University of Kentucky Markey Cancer Center, Lexington, KY. Electronic address: dennie.jones@uky.edu.
authors.forename: Dennie V
authors.initials: DV
authors.lastname: Jones
references.citation: BMC Cancer. 2005 Apr 29;5:44
references.pmid: 15862127
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
references.pmid: 9618505
references.citation: J Cell Physiol. 2005 Jan;202(1):87-99
references.pmid: 15389542
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6
references.pmid: 14734806
references.citation: Crit Rev Toxicol. 2005 Oct-Nov;35(8-9):727-38
references.pmid: 16417040
references.citation: Pathol Oncol Res. 2012 Jul;18(3):713-20
references.pmid: 22270866
references.citation: Cancer Res. 2000 Nov 1;60(21):6068-74
references.pmid: 11085529
references.citation: Cancer Discov. 2011 Dec;1(7):598-607
references.pmid: 22586682
references.citation: Mol Pharmacol. 2001 May;59(5):1269-76
references.pmid: 11306712
references.citation: Genes Dev. 2009 Apr 1;23(7):781-3
references.pmid: 19339683
references.citation: Oncol Rep. 2005 Jun;13(6):1139-44
references.pmid: 15870934
references.citation: Cancer Cell Int. 2006 Jan 31;6:2
references.pmid: 16448574
references.citation: Surgery. 2005 Dec;138(6):979-84; discussion 984-5
references.pmid: 16360381
references.citation: Cancer. 2006 Jan 1;106(1):112-9
references.pmid: 16323176
references.citation: BMC Cell Biol. 2008 Dec 09;9:66
references.pmid: 19068119
references.citation: J Neurochem. 1994 Dec;63(6):2361-4
references.pmid: 7964759
references.citation: Nature. 1998 Dec 10;396(6711):594-8
references.pmid: 9859997
references.citation: Int J Oncol. 2011 Jul;39(1):111-9
references.pmid: 21519790
references.citation: Cancer. 2005 Dec 15;104(12):2717-25
references.pmid: 16294345
references.citation: Haematologica. 2006 Feb;91(2):248-51
references.pmid: 16461312
references.citation: Mutat Res. 1993 Jan;285(1):61-7
references.pmid: 7678134
references.citation: FEBS Lett. 2003 Nov 20;554(3):347-50
references.pmid: 14623092
references.citation: J Clin Oncol. 2005 Jun 10;23(17):3971-93
references.pmid: 15897549
references.citation: Science. 2013 Mar 29;339(6127):1546-58
references.pmid: 23539594
references.citation: Mol Cancer Ther. 2005 Dec;4(12):1912-22
references.pmid: 16373706
references.citation: Oncogene. 2000 Nov 23;19(50):5712-9
references.pmid: 11126357
references.citation: Anticancer Drugs. 2002 Jan;13(1):1-13
references.pmid: 11914636
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3387-95
references.pmid: 22510351
references.citation: Clin Cancer Res. 2003 May;9(5):1596-603
references.pmid: 12738711
references.citation: Cell Prolif. 2007 Oct;40(5):640-55
references.pmid: 17877607
references.citation: J Neurooncol. 2007 Nov;85(2):159-70
references.pmid: 17534580
references.citation: Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
references.pmid: 16341240
references.citation: Oncol Rep. 2006 Jan;15(1):227-30
references.pmid: 16328060
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
references.pmid: 10954755
references.citation: Mol Cancer. 2006 Feb 20;5:8
references.pmid: 16504004
references.citation: Mol Cell. 2003 Dec;12(6):1591-8
references.pmid: 14690610
references.citation: Cancer. 2006 Mar 1;106(5):1188-96
references.pmid: 16444746
references.citation: Cancer Res. 2011 Jul 1;71(13):4373-9
references.pmid: 21527555
references.citation: Methods. 2002 Jun;27(2):179-83
references.pmid: 12095278
references.citation: Eur J Obstet Gynecol Reprod Biol. 2008 Apr;137(2):198-203
references.pmid: 17376583
references.citation: Curr Top Microbiol Immunol. 2006;301:283-315
references.pmid: 16570853
references.citation: Cancer Biol Ther. 2007 Feb;6(2):185-91
references.pmid: 17218782
references.citation: J Transl Med. 2006 Aug 07;4:32
references.pmid: 16893460
references.citation: Carcinogenesis. 2013 Aug;34(8):1900-6
references.pmid: 23568954
references.citation: J Neurosci. 2013 May 15;33(20):8621-32
references.pmid: 23678107
references.citation: Oncogene. 1995 Apr 20;10(8):1493-9
references.pmid: 7731703
references.citation: Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50
references.pmid: 9405248
references.citation: J Neurochem. 2013 Jul;126(1):4-18
references.pmid: 23647222
references.citation: Neuropharmacology. 2002 Dec;43(7):1158-64
references.pmid: 12504922